212 related articles for article (PubMed ID: 21036951)
1. Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions.
Guest EJ; Aarons L; Houston JB; Rostami-Hodjegan A; Galetin A
Drug Metab Dispos; 2011 Feb; 39(2):170-3. PubMed ID: 21036951
[TBL] [Abstract][Full Text] [Related]
2. Drug-drug interaction prediction assessment.
Zhou J; Qin Z; Sara QK; Kim S; Wang Z; Hall SD; Li L
J Biopharm Stat; 2009 Jul; 19(4):641-57. PubMed ID: 20183431
[TBL] [Abstract][Full Text] [Related]
3. Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.
Guest EJ; Rowland-Yeo K; Rostami-Hodjegan A; Tucker GT; Houston JB; Galetin A
Br J Clin Pharmacol; 2011 Jan; 71(1):72-87. PubMed ID: 21143503
[TBL] [Abstract][Full Text] [Related]
4. Drug-drug interaction prediction: a Bayesian meta-analysis approach.
Li L; Yu M; Chin R; Lucksiri A; Flockhart DA; Hall SD
Stat Med; 2007 Sep; 26(20):3700-21. PubMed ID: 17357990
[TBL] [Abstract][Full Text] [Related]
5. Use of clearance concepts and modeling techniques in the prediction of metabolic drug-drug interactions.
Ito K; Sugiyama Y
Trends Pharmacol Sci; 2010 Aug; 31(8):351-5. PubMed ID: 20542578
[TBL] [Abstract][Full Text] [Related]
6. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
Perdaems N; Blasco H; Vinson C; Chenel M; Whalley S; Cazade F; Bouzom F
Clin Pharmacokinet; 2010 Apr; 49(4):239-58. PubMed ID: 20214408
[TBL] [Abstract][Full Text] [Related]
7. Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolism data.
Shou M
Curr Opin Drug Discov Devel; 2005 Jan; 8(1):66-77. PubMed ID: 15679174
[TBL] [Abstract][Full Text] [Related]
8. Transporter-mediated drug--drug interactions involving OATP substrates: predictions based on in vitro inhibition studies.
Yoshida K; Maeda K; Sugiyama Y
Clin Pharmacol Ther; 2012 Jun; 91(6):1053-64. PubMed ID: 22534868
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the use of static and dynamic models to predict drug-drug interaction and its associated variability: impact on drug discovery and early development.
Peters SA; Schroeder PE; Giri N; Dolgos H
Drug Metab Dispos; 2012 Aug; 40(8):1495-507. PubMed ID: 22566536
[TBL] [Abstract][Full Text] [Related]
10. Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods.
Grime KH; Bird J; Ferguson D; Riley RJ
Eur J Pharm Sci; 2009 Feb; 36(2-3):175-91. PubMed ID: 19013237
[TBL] [Abstract][Full Text] [Related]
11. Bioavailability considerations in evaluating drug-drug interactions using the population pharmacokinetic approach.
Duan JZ; Jackson AJ; Zhao P
J Clin Pharmacol; 2011 Jul; 51(7):1087-100. PubMed ID: 20864622
[TBL] [Abstract][Full Text] [Related]
12. Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug development.
Boulenc X; Barberan O
Drug Metabol Drug Interact; 2011; 26(4):147-68. PubMed ID: 22149659
[TBL] [Abstract][Full Text] [Related]
13. Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist.
Lu C; Balani SK; Qian MG; Prakash SR; Ducray PS; von Moltke LL
J Pharmacol Exp Ther; 2010 Feb; 332(2):562-8. PubMed ID: 19889796
[TBL] [Abstract][Full Text] [Related]
14. Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction.
Fahmi OA; Hurst S; Plowchalk D; Cook J; Guo F; Youdim K; Dickins M; Phipps A; Darekar A; Hyland R; Obach RS
Drug Metab Dispos; 2009 Aug; 37(8):1658-66. PubMed ID: 19406954
[TBL] [Abstract][Full Text] [Related]
15. Current cytochrome P450 phenotyping methods applied to metabolic drug-drug interaction prediction in dogs.
Mills BM; Zaya MJ; Walters RR; Feenstra KL; White JA; Gagne J; Locuson CW
Drug Metab Dispos; 2010 Mar; 38(3):396-404. PubMed ID: 20007294
[TBL] [Abstract][Full Text] [Related]
16. Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors.
Wang YH
Drug Metab Dispos; 2010 Jul; 38(7):1094-104. PubMed ID: 20368327
[TBL] [Abstract][Full Text] [Related]
17. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.
Chien JY; Lucksiri A; Ernest CS; Gorski JC; Wrighton SA; Hall SD
Drug Metab Dispos; 2006 Jul; 34(7):1208-19. PubMed ID: 16611859
[TBL] [Abstract][Full Text] [Related]
18. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs.
De Buck SS; Sinha VK; Fenu LA; Nijsen MJ; Mackie CE; Gilissen RA
Drug Metab Dispos; 2007 Oct; 35(10):1766-80. PubMed ID: 17620347
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma.
Niioka T; Uno T; Yasui-Furukori N; Takahata T; Shimizu M; Sugawara K; Tateishi T
Cancer Chemother Pharmacol; 2007 Apr; 59(5):575-80. PubMed ID: 16912889
[TBL] [Abstract][Full Text] [Related]
20. Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants.
Bachmann KA; Lewis JD
Ann Pharmacother; 2005 Jun; 39(6):1064-72. PubMed ID: 15886285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
